Cornea

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Rare retinal diseases initially were the primary targets of gene therapy, but that is no longer the case. The focus has expanded beyond those to also include more common, chronic diseases such as diabetic macular edema and wet age-related macular degeneration. During the first half of 2026, that trend was evident.

The FDA issued a nationwide recall of a steroid eye drop.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

Ophthalmology Times® On Air

A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.

A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction

Engineered ocular bacteria act as a long-lasting eye drop, secreting IL-10 to speed corneal healing and hint at future living therapies.

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date